Drug Trial Radar · NCT05769946
A Study of Hemay005 in Adult With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Nov 24, 2022
Primary completion
Jan 24, 2024
Study completion Feb 21, 2024
Sponsor
- Lead sponsor
- Ganzhou Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
Conditions
- Hemay005, Atopic Dermatitis
Interventions
Hemay005Drug
A PDE-4 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- EASI-75Time frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.